ONGA
RPRX icon

O'Neil Global Advisors’s Royalty Pharma RPRX Stock Holding History

O'Neil Global Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19,844
Closed -$715K – 82
2025
Q2 		$715K Buy
+19,844
New +$657K 0.16% 47

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

O'Neil Global Advisors's RPRX Position: Q3 2025 in Review

O'Neil Global Advisors sold out of Royalty Pharma (RPRX) in Q3 2025, closing a stake of 19,844 shares — an estimated $715K sold.

O'Neil Global Advisors first reported a position in RPRX in Q2 2025 and held it in 1 quarter. The position peaked at $715K in Q2 2025. 487 funds tracked by Wall St. Rank hold RPRX as of Q3 2025.

  • O'Neil Global Advisors reported no remaining Royalty Pharma position as of Q3 2025 after selling out during the quarter.
  • O'Neil Global Advisors sold 19,844 Royalty Pharma shares in Q3 2025, an estimated $715K.
  • O'Neil Global Advisors first reported a position in Royalty Pharma in Q2 2025 and held it in 1 quarter.
  • O'Neil Global Advisors's Royalty Pharma position peaked at $715K in Q2 2025.
  • 487 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2025.

Based on O'Neil Global Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.